Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-Ignite phase 3 rocatinlimab monotherapy in moderate-to-severe atopic dermatitis
NL-OMON60853Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Primary endpoints: vIGA-AD 0/1 response at week 24 and EASI 75 at week 24. Started Jun 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON60853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60853.